Clinical trials report gastrointestinal adverse events in 25-40% of participants, with severity often declining after 4-8 weeks of continued use
ClinicalTrials.gov Mazdutide Trial Registry: lists registered studies and recruitment details when available
This is a common question amongst patients starting this type 2 diabetes medication
TheScientificWorldJ 2015:716749
Today, the high prices and periodic shortages often observed with GLP-1R agonists limit equitable access, underscoring the importance of policy action, stable manufacturing, and fair distribution
While heart health is a current benefit of Semaglutide, current studies show that Tirzepatide might be more effective as a weight loss medication due to its higher dosage than Semaglutide, with many patients experiencing milder side effects overall